Predictive value of IL-18 and IL-10 in the prognosis of patients with colorectal cancer

Li,Baosong; Wang,Fengxia; Ma,Chong; Hao,Tao; Geng,Longlong; Jiang,Hong

doi:10.3892/ol.2019.10338

Predictive value of IL-18 and IL-10 in the prognosis of patients with colorectal cancer

Authors:
- Baosong Li
- Fengxia Wang
- Chong Ma
- Tao Hao
- Longlong Geng
- Hong Jiang
View Affiliations

Affiliations: Department of Colorectal and Anal Surgery, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China, Department of Laboratory, Binzhou Medical University Hospital, Binzhou, Shandong 256603, P.R. China
Published online on: May 8, 2019 https://doi.org/10.3892/ol.2019.10338
Pages: 713-719
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Predictive value of serum interleukin 10 (IL-10) and interleukin 18 (IL-18) expression in patients with colorectal cancer (CRC) was investigated. This study retrospectively analyzed the medical records of 146 patients with CRC admitted to the Binzhou Medical University Hospital as the study group, and collected the physical examination data of 82 volunteers as the control group. The expression levels of IL-10 and IL-18 in the serum were measured by enzyme-linked immunosorbent assay (ELISA). A 60-month follow-up on patients in the study group was performed to make records of their prognosis. The expressions of IL-10 and IL-18 were statistically different in patients with different Dukes' stages, tumor sizes, histological grades, and different situations of distant metastasis of cancer cells (P<0.05); with a gradual downward trend following the operation. The expression levels of serum IL-10 and IL-18 in the study group 7 days after the operation were lower than the levels before the operation (P<0.05), and the expression levels of IL-10 and IL-18 of patients in the study group on the day of discharge were lower than the expression levels 7 days after the operation (P<0.05). The expressions of IL-10 and IL-18 of patients with reoccurred CRC after the operation were significantly higher than that of patients without recurrence of CRC in the study group (P<0.05). Thus, IL-10 and IL-18 are highly expressed in the serum of CRC patients, which makes IL-10 and IL-18 useful to serve as indicators to determine the prognosis of CRC patients. The lower the expression levels of IL-10 and IL-18, the lower the cancer recurrence rate, the better the prognosis and the longer the survival time.

View Figures

View References

1	Ren XL, He GY, Li XM, Men H, Yi LZ, Lu GF, Xin SN, Wu PX, Li YL, Liao WT, et al: MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2. J Cancer Res Clin Oncol. 142:581–592. 2016. View Article : Google Scholar : PubMed/NCBI
2	Burden ST, Hill J, Shaffer JL and Todd C: Nutritional status of preoperative colorectal cancer patients. J Hum Nutr Diet. 23:402–407. 2010. View Article : Google Scholar : PubMed/NCBI
3	Rasmussen S, Larsen PV, Søndergaard J, Elnegaard S, Svendsen RP and Jarbøl DE: Specific and non-specific symptoms of colorectal cancer and contact to general practice. Fam Pract. 32:387–394. 2015.PubMed/NCBI
4	Cerdán-Santacruz C, Cano-Valderrama O, Cárdenas-Crespo S, Torres-García AJ and Cerdán-Miguel J: Colorectal cancer and its delayed diagnosis: Have we improved in the past 25 years? Rev Esp Enferm Dig. 103:458–463. 2011. View Article : Google Scholar : PubMed/NCBI
5	Zippi M, De Toma G, Minervini G, Cassieri C, Pica R, Colarusso D, Stock S and Crispino P: Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy. Saudi J Gastroenterol. 23:39–44. 2017. View Article : Google Scholar : PubMed/NCBI
6	Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS and Nagarkatti M: Role of cytokines as a double-edged sword in sepsis. In Vivo. 27:669–684. 2013.PubMed/NCBI
7	Liu M, Zhao X and Ma Y, Zhou Y, Deng M and Ma Y: Transcription factor c-Maf is essential for IL-10 gene expression in B cells. Scand J Immunol. 88:e127012018. View Article : Google Scholar : PubMed/NCBI
8	Tabibzadeh S, Becker JL and Parsons AK: Endometriosis is associated with alterations in the relative abundance of proteins and IL-10 in the peritoneal fluid. Front Biosci. 8:a70–a78. 2003. View Article : Google Scholar : PubMed/NCBI
9	Hamzavi M, Tadbir AA, Rezvani G, Ashraf MJ, Fattahi MJ, Khademi B, Sardari Y and Jeirudi N: Tissue expression, serum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev. 14:1681–1685. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wu SQ, Liang W, Wang GL, Li LY, Wang DL and Chen C: Polymorphisms of the IL-18 promoter and bronchial asthma. Mol Med Rep. 6:1385–1388. 2012. View Article : Google Scholar : PubMed/NCBI
11	Cornish J, Gillespie MT, Callon KE, Horwood NJ, Moseley JM and Reid IR: Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology. 144:1194–1201. 2003. View Article : Google Scholar : PubMed/NCBI
12	Liu W, Hu M, Wang Y, Sun B, Guo Y, Xu Z, Li J and Han B: Overexpression of interleukin-18 protein reduces viability and induces apoptosis of tongue squamous cell carcinoma cells by activation of glycogen synthase kinase-3β signaling. Oncol Rep. 33:1049–1056. 2015. View Article : Google Scholar : PubMed/NCBI
13	Long X, Li R, Yang Y and Qiao J: Overexpression of IL-18 in the proliferative phase endometrium of patients with polycystic ovary syndrome. Reprod Sci. 24:252–257. 2017. View Article : Google Scholar : PubMed/NCBI
14	Ress AL, Perakis S and Pichler M: microRNAs and colorectal cancer. Adv Exp Med Biol. 889:89–103. 2015. View Article : Google Scholar : PubMed/NCBI
15	Goldvaser H, Purim O, Kundel Y, Shepshelovich D, Shochat T, Shemesh-Bar L, Sulkes A and Brenner B: Colorectal cancer in young patients: Is it a distinct clinical entity? Int J Clin Oncol. 21:684–695. 2016. View Article : Google Scholar : PubMed/NCBI
16	Zheng Y and Wu C: Prevalence and trend of gastrointestinal malignant tumors in the elderly over 75 years old in China. Zhonghua Wei Chang Wai Ke Za Zhi. 19:481–485. 2016.(In Chinese). PubMed/NCBI
17	Castells A: Prevention of colorectal cancer. Med Clin (Barc). 117:69–75. 2001.(In Spanish). View Article : Google Scholar : PubMed/NCBI
18	Hind R, Rew DR and Johnson CD: Surgical excision alone is adequate treatment for primary colorectal cancer. Ann R Coll Surg Engl. 74:63–67. 1992.PubMed/NCBI
19	Sio A, Chehal MK, Tsai K, Fan X, Roberts ME, Nelson BH, Grembecka J, Cierpicki T, Krebs DL and Harder KW: Dysresgulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells. Cancer Res. 73:5892–5904. 2013. View Article : Google Scholar : PubMed/NCBI
20	Mittal SK and Roche PA: Suppression of antigen presentation by IL-10. Curr Opin Immunol. 34:22–27. 2015. View Article : Google Scholar : PubMed/NCBI
21	Dwivedi S, Goel A, Natu SM, Mandhani A, Khattri S and Pant KK: Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: A prospective study. Asian Pac J Cancer Prev. 12:1843–1848. 2011.PubMed/NCBI
22	Amerio P, Frezzolini A, Abeni D, Teofoli P, Girardelli CR, De Pità O and Puddu P: Increased IL-18 in patients with systemic lupus erythematosus: Relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol. 20:535–538. 2002.PubMed/NCBI
23	Li X, Ren D, Li Y, Xu J, Liu C and Zhao Y: Increased cancer risk associated with the −607C/A polymorphism in interleukin-18 gene promoter: An updated meta-analysis including 12,502 subjects. J BUON. 20:902–917. 2015.PubMed/NCBI
24	Jablonska E, Puzewska W, Grabowska Z, Jablonski J and Talarek L: VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine. 30:93–99. 2005. View Article : Google Scholar : PubMed/NCBI
25	Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S and Ghaderi A: IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol. 24:1119–1122. 2009. View Article : Google Scholar : PubMed/NCBI
26	Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C and De Vita F: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol. 102:169–178. 2002. View Article : Google Scholar : PubMed/NCBI
27	Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S and Neurath MF: IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle. 4:217–220. 2005. View Article : Google Scholar : PubMed/NCBI
28	Miteva LD, Stanilov NS, Deliysky TS and Stanilova SA: Significance of −1082A/G polymorphism of IL-10 gene for progression of colorectal cancer and IL-10 expression. Tumour Biol. 35:12655–12664. 2014. View Article : Google Scholar : PubMed/NCBI
29	Okamoto M, Azuma K, Hoshino T, Imaoka H, Ikeda J, Kinoshita T, Takamori S, Ohshima K, Edakuni N, Kato S, et al: Correlation of decreased survival and IL-18 in bone metastasis. Intern Med. 48:763–773. 2009. View Article : Google Scholar : PubMed/NCBI